Peripheral Blood Stem Cell TransplantationHematopoietic Stem Cell TransplantationTransplantation, HomologousGraft vs Host DiseaseTransplantation ConditioningHematologic NeoplasmsTransplantation, AutologousStem Cell TransplantationHematopoietic Stem Cell MobilizationGraft SurvivalTransplantation ChimeraGranulocyte Colony-Stimulating FactorBone Marrow TransplantationBusulfanTissue DonorsAntigens, CD34Treatment OutcomeVidarabineImmunosuppressive AgentsLeukapheresisRecurrenceMyeloablative AgonistsGraft vs Leukemia EffectStem CellsMelphalanCombined Modality TherapyKidney TransplantationHistocompatibility TestingHistocompatibilityMultiple MyelomaHematopoietic Stem CellsRemission InductionRetrospective StudiesCord Blood Stem Cell TransplantationCyclophosphamideSurvival AnalysisLeukemiaWhole-Body IrradiationBlood Component RemovalAntineoplastic Combined Chemotherapy ProtocolsLiver TransplantationDisease-Free SurvivalTime FactorsGraft RejectionLeukemia, Myeloid, AcuteSalvage TherapyLymphoma, Non-HodgkinSurvival RatePrecursor Cell Lymphoblastic Leukemia-LymphomaGraft vs Tumor EffectCytomegalovirus InfectionsEtoposideTransplantation, IsogeneicLeukemia, Myelogenous, Chronic, BCR-ABL PositiveLymphocyte TransfusionHLA AntigensMyelodysplastic SyndromesChronic DiseaseLymphocyte DepletionAntineoplastic Agents, AlkylatingInfectionT-LymphocytesTransplantation ImmunologyCytarabineThiotepaAnemia, AplasticHodgkin DiseaseSiblingsHematopoiesisFollow-Up StudiesCyclosporinePOEMS SyndromeMesenchymal Stem Cell TransplantationNeoplasm, ResidualCell TransplantationImmunosuppressionHematologic DiseasesVincristineAntilymphocyte SerumAmyloidosisCarmustineFatal OutcomeAcute DiseaseLymphomaHeart TransplantationBlood CellsPrognosisOpportunistic InfectionsChimerismIfosfamideEmbryonic Stem CellsHepatic Veno-Occlusive DiseaseMinor Histocompatibility AntigensBone MarrowProspective StudiesAntineoplastic AgentsPlatelet CountLung TransplantationImmunophenotypingVirus Activation